Roby Paul Bhattacharyya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Roby Paul Bhattacharyya has a total of 318 co-authors. Here are the top co-authors by number of shared publications:
- Deborah T. Hung
Broad Institute of MIT and Harvard, Cambridge, USA
9 shared publications Jonathan Livny
Broad Institute of MIT and Harvard , Cambridge, MA 02142 , USA
6 shared publications- Christina A. Cuomo
Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard
5 shared publications - Paul C. Blainey
Massachusetts Institute of Technology
5 shared publications - Abigail Manson McGuire
Infectious Disease and Microbiome Program, Broad Institute, Cambridge, Massachusetts, USA
4 shared publications - David Roach
Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA
4 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14  (11)
An rRNA hybridization-based approach for rapid and accurate identification of diverse fungal pathogens
Invasive fungal infections are a global threat for which early diagnosis is critical for patient outcomes, but current diagnostic measures remain notoriously slow. Here, we extend our multiplexed, hybridization-based rRNA-targeted strategy for rapid, sensitive pathogen identification, previously designed for diverse bacteria and Candida species, to identify diverse fungal pathogens. We created a set of 91 probes targeting 86 medically relevant fungal species, designed to recognize regions of differential conservation across taxonomic groupings, from class- to species-specific probes. We assessed assay performance across a Training Set of 93 clinical isolates spanning 32 species of common fungal pathogens across 18 genera, with Pearson correlations of probeset reactivity profiles identifying the pathogen at the species, genus, and family level with 83%, 94%, and 95% accuracy, respectively, in a leave-one-out analysis. We developed a new classifier on this Training Set, using taxonomic categories to select progressively more informative probes at each taxonomic level. After optimization, we assessed performance on an independent Validation Set of 54 clinical isolates spanning the same species as the Training Set, with 91%, 94%, and 98% at the species, genus, and family levels, respectively. We piloted our assay on formalin-fixed paraffin-embedded (FFPE) tissue, demonstrating rapid, culture-independent fungal identification from this high-value clinical sample type, often the sole specimen available. The assay requires <30 min hands-on time (or <65 min from FFPE tissue), returning results in <8 h from cultured specimen on an RNA detection platform available in clinical laboratories. IMPORTANCE: Timely identification of fungal pathogens is critical for patient outcomes. Here we describe a multiplexed hybridization-based assay targeting rRNA that capitalizes on the high sequence conservation and abundance of rRNA to generate unique reactivity profiles that serve as “fingerprints” of diverse fungal pathogens. By comparing these fingerprints to a Training Set of known isolates, this novel assay enables accurate identification of 32 species of pathogenic fungi from crude lysates of cultured clinical isolates.
- 3 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14  (11)
Open AccessAn rRNA hybridization-based approach for rapid and accurate identification of diverse fungal pathogens
Invasive fungal infections are a global threat for which early diagnosis is critical for patient outcomes, but current diagnostic measures remain notoriously slow. Here, we extend our multiplexed, hybridization-based rRNA-targeted strategy for rapid, sensitive pathogen identification, previously designed for diverse bacteria and Candida species, to identify diverse fungal pathogens. We created a set of 91 probes targeting 86 medically relevant fungal species, designed to recognize regions of differential conservation across taxonomic groupings, from class- to species-specific probes. We assessed assay performance across a Training Set of 93 clinical isolates spanning 32 species of common fungal pathogens across 18 genera, with Pearson correlations of probeset reactivity profiles identifying the pathogen at the species, genus, and family level with 83%, 94%, and 95% accuracy, respectively, in a leave-one-out analysis. We developed a new classifier on this Training Set, using taxonomic categories to select progressively more informative probes at each taxonomic level. After optimization, we assessed performance on an independent Validation Set of 54 clinical isolates spanning the same species as the Training Set, with 91%, 94%, and 98% at the species, genus, and family levels, respectively. We piloted our assay on formalin-fixed paraffin-embedded (FFPE) tissue, demonstrating rapid, culture-independent fungal identification from this high-value clinical sample type, often the sole specimen available. The assay requires <30 min hands-on time (or <65 min from FFPE tissue), returning results in <8 h from cultured specimen on an RNA detection platform available in clinical laboratories. IMPORTANCE: Timely identification of fungal pathogens is critical for patient outcomes. Here we describe a multiplexed hybridization-based assay targeting rRNA that capitalizes on the high sequence conservation and abundance of rRNA to generate unique reactivity profiles that serve as “fingerprints” of diverse fungal pathogens. By comparing these fingerprints to a Training Set of known isolates, this novel assay enables accurate identification of 32 species of pathogenic fungi from crude lysates of cultured clinical isolates.
- 2 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12  (40)
A rapid, inexpensive diagnostic for bacterial pathogen and resistance detection in resource-limited settings
Antimicrobial resistance is a major global health threat, with disproportionate impact in regions with limited diagnostic infrastructure. To address this challenge, we developed BADLOCK (Bacterial and AMR Detection by SHERLOCK), a rapid, low-cost molecular diagnostic platform for direct detection of bacterial pathogens and resistance genes from clinical samples. BADLOCK operates as a one-pot CRISPR-Cas13a reaction capable of detecting nine bacterial species and four major resistance genes directly from positive blood culture. It requires only a heat block and a basic fluorometer for operation. We validated BADLOCK on 194 sequentially collected clinical blood culture specimens growing Gram-negative rods, supplemented with 69 mock samples generated from banked isolates enriched for targeted resistance genes. In all, we conducted 2224 individual reactions, achieving 97.6% accuracy (2171 of 2224) at the reaction level. At the assay level, 89.5% (274 of 306) showed perfect or partial concordance with gold-standard species and resistance gene detection, including 255 assays with perfect concordance and 19 with partial concordance (correct detection of at least one pathogen). This included an evaluation of BADLOCK as a potential culture-free diagnostic for urinary tract infections (UTIs), achieving 98.0% reaction-level accuracy. At the assay level, 95.3% (41 of 43) were partially or perfectly concordant with gold-standard detection of both species and resistance genes. To our knowledge, this represents the first demonstration of the CRISPR-Cas13a diagnostic platform on clinical bloodstream infections to date and supports BADLOCK’s potential as a practical and scalable solution for rapid pathogen and resistance gene detection in resource-constrained settings.
- 2 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12  (40)
A rapid, inexpensive diagnostic for bacterial pathogen and resistance detection in resource-limited settings
Antimicrobial resistance is a major global health threat, with disproportionate impact in regions with limited diagnostic infrastructure. To address this challenge, we developed BADLOCK (Bacterial and AMR Detection by SHERLOCK), a rapid, low-cost molecular diagnostic platform for direct detection of bacterial pathogens and resistance genes from clinical samples. BADLOCK operates as a one-pot CRISPR-Cas13a reaction capable of detecting nine bacterial species and four major resistance genes directly from positive blood culture. It requires only a heat block and a basic fluorometer for operation. We validated BADLOCK on 194 sequentially collected clinical blood culture specimens growing Gram-negative rods, supplemented with 69 mock samples generated from banked isolates enriched for targeted resistance genes. In all, we conducted 2224 individual reactions, achieving 97.6% accuracy (2171 of 2224) at the reaction level. At the assay level, 89.5% (274 of 306) showed perfect or partial concordance with gold-standard species and resistance gene detection, including 255 assays with perfect concordance and 19 with partial concordance (correct detection of at least one pathogen). This included an evaluation of BADLOCK as a potential culture-free diagnostic for urinary tract infections (UTIs), achieving 98.0% reaction-level accuracy. At the assay level, 95.3% (41 of 43) were partially or perfectly concordant with gold-standard detection of both species and resistance genes. To our knowledge, this represents the first demonstration of the CRISPR-Cas13a diagnostic platform on clinical bloodstream infections to date and supports BADLOCK’s potential as a practical and scalable solution for rapid pathogen and resistance gene detection in resource-constrained settings.
- Open Access
Phased amplicon multiplex sequencing for cost-effective detection of high-risk human papillomavirus from cervical samples
Access to accurate cost-effective technologies for typing high-risk human papillomaviruses (hrHPV) is critical to expand cervical cancer screening and inform vaccination strategies. Compared with clinical-standard quantitative polymerase chain reaction (qPCR) assays, HPV genotyping by next-generation sequencing (NGS) provides greater flexibility, scalability, and genotype specificity. We have developed a method for HPV genotyping, HPV Phased Amplicon Multiplex Sequencing (PhAM-Seq), that uses combinatorial barcoding of amplicons with short, variable-length inline sequences to enable higher throughput and lower per-sample costs than conventional amplicon sequencing approaches. We evaluated HPV PhAM-Seq using degenerate and type-specific primers targeting the L1 and E6-E7 gene loci in a blinded cohort of 170 cervical samples previously typed by the Seegene Anyplex II HPV28 Detection qPCR assay. Across eight common hrHPV types (HPV16, 18, 31, 33, 35, 45, 52, and 58), HPV PhAM-Seq demonstrated >80% overall agreement with qPCR using degenerate L1-targeting primers, with the highest sensitivity for HPV16, 31, 33, and 58. Sensitivity for HPV35, 45, and 52 improved to 85% or greater with type-specific primers targeting genes E6/E7. Parallel processing and sequencing enables a single technician to assay hundreds of samples per week at a reagent cost of around $10 USD per sample, with laboratory automation and sequencing on higher-output platforms enabling further scaling and cost reduction to a scale amenable to population-level surveillance. We include a detailed SOP; tools for primer design, sequencing library construction, and sample tracking; and all scripts needed for data analysis to ensure HPV PhAM-Seq can be readily implemented for scalable, cost-effective hrHPV genotyping or extended to other similar applications.
Open AccessPhased amplicon multiplex sequencing for cost-effective detection of high-risk human papillomavirus from cervical samples
Access to accurate cost-effective technologies for typing high-risk human papillomaviruses (hrHPV) is critical to expand cervical cancer screening and inform vaccination strategies. Compared with clinical-standard quantitative polymerase chain reaction (qPCR) assays, HPV genotyping by next-generation sequencing (NGS) provides greater flexibility, scalability, and genotype specificity. We have developed a method for HPV genotyping, HPV Phased Amplicon Multiplex Sequencing (PhAM-Seq), that uses combinatorial barcoding of amplicons with short, variable-length inline sequences to enable higher throughput and lower per-sample costs than conventional amplicon sequencing approaches. We evaluated HPV PhAM-Seq using degenerate and type-specific primers targeting the L1 and E6-E7 gene loci in a blinded cohort of 170 cervical samples previously typed by the Seegene Anyplex II HPV28 Detection qPCR assay. Across eight common hrHPV types (HPV16, 18, 31, 33, 35, 45, 52, and 58), HPV PhAM-Seq demonstrated >80% overall agreement with qPCR using degenerate L1-targeting primers, with the highest sensitivity for HPV16, 31, 33, and 58. Sensitivity for HPV35, 45, and 52 improved to 85% or greater with type-specific primers targeting genes E6/E7. Parallel processing and sequencing enables a single technician to assay hundreds of samples per week at a reagent cost of around $10 USD per sample, with laboratory automation and sequencing on higher-output platforms enabling further scaling and cost reduction to a scale amenable to population-level surveillance. We include a detailed SOP; tools for primer design, sequencing library construction, and sample tracking; and all scripts needed for data analysis to ensure HPV PhAM-Seq can be readily implemented for scalable, cost-effective hrHPV genotyping or extended to other similar applications.
- Open Access
- 10 July 2026
- Published by Springer Nature in npj Antimicrobials and Resistance
- Vol. 4  (1)
Low-cost approaches for detecting antimicrobial resistance in bacterial infections in resource-limited settings: a scoping review
Antimicrobial resistance (AMR) poses a growing global threat, with low- and middle-income countries (LMICs) bearing a disproportionate burden of resistant infections. Detection of resistance is critical for guiding treatment, enabling stewardship, and supporting surveillance, yet diagnostic capacity in LMICs remains severely limited. We conducted a scoping review to map low-cost diagnostic approaches suitable for resource-limited settings for detecting AMR in bacterial infections, excluding tuberculosis. Following PRISMA-ScR guidelines, we screened 585 articles and included 61 studies, which we evaluated using a framework based on the WHO REASSURED criteria. Genotypic approaches predominated (39 studies) while 22 studies employed phenotypic approaches. The majority (72%) were proof-of-concept studies, only 8 were implemented in LMICs, and just 2 assessed clinical outcomes. Critical gaps included limited validation on clinical specimens, near-absent cost data, high infrastructural requirements, and inconsistent reporting of performance metrics. To address reporting heterogeneity and improve knowledge gaps, we propose the REACH checklist (Readiness and design, Execution and workflow, Access requirements, Clinical and analytical performance, and Health outcomes and economics) as a reporting framework derived directly from the gaps identified across included studies, intended to span AMR diagnostic development from proof-of-concept through clinical validation relevant to low-resource settings.
- 10 July 2026
- Published by Springer Nature in npj Antimicrobials and Resistance
- Vol. 4  (1)
Open AccessLow-cost approaches for detecting antimicrobial resistance in bacterial infections in resource-limited settings: a scoping review
Antimicrobial resistance (AMR) poses a growing global threat, with low- and middle-income countries (LMICs) bearing a disproportionate burden of resistant infections. Detection of resistance is critical for guiding treatment, enabling stewardship, and supporting surveillance, yet diagnostic capacity in LMICs remains severely limited. We conducted a scoping review to map low-cost diagnostic approaches suitable for resource-limited settings for detecting AMR in bacterial infections, excluding tuberculosis. Following PRISMA-ScR guidelines, we screened 585 articles and included 61 studies, which we evaluated using a framework based on the WHO REASSURED criteria. Genotypic approaches predominated (39 studies) while 22 studies employed phenotypic approaches. The majority (72%) were proof-of-concept studies, only 8 were implemented in LMICs, and just 2 assessed clinical outcomes. Critical gaps included limited validation on clinical specimens, near-absent cost data, high infrastructural requirements, and inconsistent reporting of performance metrics. To address reporting heterogeneity and improve knowledge gaps, we propose the REACH checklist (Readiness and design, Execution and workflow, Access requirements, Clinical and analytical performance, and Health outcomes and economics) as a reporting framework derived directly from the gaps identified across included studies, intended to span AMR diagnostic development from proof-of-concept through clinical validation relevant to low-resource settings.
- Open Access
A rRNA hybridization-based approach for rapid and accurate identification of diverse fungal pathogens
Invasive fungal infections are a global threat; early diagnosis is critical for patient outcomes, but current diagnostic measures remain notoriously slow. Here we extend our multiplexed, hybridization-based rRNA-targeted strategy for rapid, sensitive pathogen identification, previously designed for diverse bacteria and Candida species, to identify diverse fungal pathogens. We created a set of 91 probes targeting 86 medically relevant fungal species, designed to recognize regions of differential conservation across taxonomic groupings, from class- to species-specific probes. We assessed assay performance across a Training Set of 93 clinical isolates spanning 32 species of common fungal pathogens across 18 genera, with Pearson correlations of probeset reactivity profiles (PSRPs) identifying the pathogen at the species, genus, and family level with 83%, 94%, and 95% accuracy, respectively, in a leave-one-out analysis. We developed a more sophisticated classifier on this Training Set, using taxonomic categories to select progressively more informative probes at each taxonomic level. After optimization, we assessed performance on an independent Validation Set of 54 clinical isolates spanning the same species as the Training Set, with 91%, 94%, and 98% at the species, genus, and family levels, respectively. We piloted our assay on formalin-fixed paraffin-embedded (FFPE) tissue, demonstrating rapid, culture-independent fungal identification from this high-value clinical sample type, often the sole specimen available. The assay requires <30 minutes hands-on time (or <65 minutes from FFPE tissue), returning results in 50 species of pathogenic fungi from crude lysates of cultured clinical isolates.
Open AccessA rRNA hybridization-based approach for rapid and accurate identification of diverse fungal pathogens
Invasive fungal infections are a global threat; early diagnosis is critical for patient outcomes, but current diagnostic measures remain notoriously slow. Here we extend our multiplexed, hybridization-based rRNA-targeted strategy for rapid, sensitive pathogen identification, previously designed for diverse bacteria and Candida species, to identify diverse fungal pathogens. We created a set of 91 probes targeting 86 medically relevant fungal species, designed to recognize regions of differential conservation across taxonomic groupings, from class- to species-specific probes. We assessed assay performance across a Training Set of 93 clinical isolates spanning 32 species of common fungal pathogens across 18 genera, with Pearson correlations of probeset reactivity profiles (PSRPs) identifying the pathogen at the species, genus, and family level with 83%, 94%, and 95% accuracy, respectively, in a leave-one-out analysis. We developed a more sophisticated classifier on this Training Set, using taxonomic categories to select progressively more informative probes at each taxonomic level. After optimization, we assessed performance on an independent Validation Set of 54 clinical isolates spanning the same species as the Training Set, with 91%, 94%, and 98% at the species, genus, and family levels, respectively. We piloted our assay on formalin-fixed paraffin-embedded (FFPE) tissue, demonstrating rapid, culture-independent fungal identification from this high-value clinical sample type, often the sole specimen available. The assay requires <30 minutes hands-on time (or <65 minutes from FFPE tissue), returning results in 50 species of pathogenic fungi from crude lysates of cultured clinical isolates.
- Open Access
- 12 November 2025
- Published by American Society for Microbiology in mBio
- Vol. 16  (11) , e0154025
The carbapenem inoculum effect provides insights into the molecular mechanisms underlying carbapenem resistance in the Enterobacterales
Carbapenem-resistant Enterobacterales (CRE) are important pathogens that can develop resistance via multiple molecular mechanisms, including hydrolysis or reduced antibiotic influx. Identifying these mechanisms can improve pathogen surveillance, infection control, and patient care. We investigated, both phenomenologically and mechanistically, how resistance mechanisms influence the carbapenem inoculum effect (IE), a phenomenon where inoculum size affects antimicrobial susceptibility testing (AST). We demonstrated that any of seven different carbapenemases were sufficient to impart a meropenem IE when transformed into a laboratory strain of Escherichia coli . Across 106 clinical CRE isolates spanning 6 genera and 12 species, the carbapenem IE strictly depended on resistance mechanism: all 36 carbapenemase-producing CRE (CP-CRE) exhibited a clear IE, whereas 43 porin-deficient CRE displayed none. Twenty-seven isolates with both carbapenemase production and porin deficiency exhibited high-level resistance at all inocula and still displayed an IE, albeit smaller in magnitude than CP-CRE with intact porins. Mechanistically, we found that CP-CRE released carbapenemase activity into the culture supernatant to protect other cells, and this released activity markedly increased upon exposure to lethal antibiotic doses. Concerningly, 50% and 24% of CP-CRE isolates changed susceptibility classification to meropenem and ertapenem, respectively, across the allowable inoculum range in clinical testing guidelines. The meropenem IE and the ratio of ertapenem to meropenem minimal inhibitory concentration (MIC) at standard inoculum reliably identified CP-CRE. Understanding how resistance mechanisms affect AST could improve diagnosis and guide therapies for CRE infections. IMPORTANCE: Infections caused by carbapenem-resistant Enterobacterales (CRE) pose significant threats to patients and public health worldwide. Carbapenem resistance can occur through several molecular mechanisms, including enzymatic hydrolysis by carbapenemases and reduced influx via porin mutations. Identifying carbapenemase-producing isolates could enable tailored antibiotic selection to improve patient outcomes and infection control measures to prevent further carbapenemase transmission. In a large collection of CRE isolates, we found that only carbapenemase-producing CRE exhibited an inoculum effect, in which their measured resistance varies markedly with cell density, which risks misdiagnosis. Further, this inoculum effect occurred under conditions where bacteria released carbapenemases to the community upon exposure to antibiotics that resulted in cell death. Measuring this inoculum effect, or integrating other data from routine antimicrobial susceptibility testing, enhanced carbapenem resistance detection, paving the way for more effective strategies to combat this growing public health crisis.
- 12 November 2025
- Published by American Society for Microbiology in mBio
- Vol. 16  (11) , e0154025
Open AccessThe carbapenem inoculum effect provides insights into the molecular mechanisms underlying carbapenem resistance in the Enterobacterales
Carbapenem-resistant Enterobacterales (CRE) are important pathogens that can develop resistance via multiple molecular mechanisms, including hydrolysis or reduced antibiotic influx. Identifying these mechanisms can improve pathogen surveillance, infection control, and patient care. We investigated, both phenomenologically and mechanistically, how resistance mechanisms influence the carbapenem inoculum effect (IE), a phenomenon where inoculum size affects antimicrobial susceptibility testing (AST). We demonstrated that any of seven different carbapenemases were sufficient to impart a meropenem IE when transformed into a laboratory strain of Escherichia coli . Across 106 clinical CRE isolates spanning 6 genera and 12 species, the carbapenem IE strictly depended on resistance mechanism: all 36 carbapenemase-producing CRE (CP-CRE) exhibited a clear IE, whereas 43 porin-deficient CRE displayed none. Twenty-seven isolates with both carbapenemase production and porin deficiency exhibited high-level resistance at all inocula and still displayed an IE, albeit smaller in magnitude than CP-CRE with intact porins. Mechanistically, we found that CP-CRE released carbapenemase activity into the culture supernatant to protect other cells, and this released activity markedly increased upon exposure to lethal antibiotic doses. Concerningly, 50% and 24% of CP-CRE isolates changed susceptibility classification to meropenem and ertapenem, respectively, across the allowable inoculum range in clinical testing guidelines. The meropenem IE and the ratio of ertapenem to meropenem minimal inhibitory concentration (MIC) at standard inoculum reliably identified CP-CRE. Understanding how resistance mechanisms affect AST could improve diagnosis and guide therapies for CRE infections. IMPORTANCE: Infections caused by carbapenem-resistant Enterobacterales (CRE) pose significant threats to patients and public health worldwide. Carbapenem resistance can occur through several molecular mechanisms, including enzymatic hydrolysis by carbapenemases and reduced influx via porin mutations. Identifying carbapenemase-producing isolates could enable tailored antibiotic selection to improve patient outcomes and infection control measures to prevent further carbapenemase transmission. In a large collection of CRE isolates, we found that only carbapenemase-producing CRE exhibited an inoculum effect, in which their measured resistance varies markedly with cell density, which risks misdiagnosis. Further, this inoculum effect occurred under conditions where bacteria released carbapenemases to the community upon exposure to antibiotics that resulted in cell death. Measuring this inoculum effect, or integrating other data from routine antimicrobial susceptibility testing, enhanced carbapenem resistance detection, paving the way for more effective strategies to combat this growing public health crisis.
- Open Access
A multimodal atlas of COVID-19 severity identifies hallmarks of dysregulated immunity
The alpha-variant wave of the COVID-19 pandemic provided a unique opportunity to study, at single-cell resolution, how near-universal exposure to the same pathogen can lead to either effective or dysfunctional immune responses in humans. Although single-cell RNA-sequencing studies have characterized immune cellular features of COVID-19, they have not shown how tocilizumab treatment changes these features at single-cell resolution, or which features might persist into convalescence. In this study, we analyzed 2.5 million circulating immune cells from 428 patients across time points (840 PBMC samples), encompassing three contemporaneous SARS-CoV-2 cohorts: acutely infected patients across five WHO disease severity levels and three time points, patients from the first randomized control trial to study the efficacy of tocilizumab in the management of COVID-19, and convalescent patients three months after infection. We used linear modeling to integrate multiple data types – including single-cell RNA-seq, CITE-seq, TCR and BCR sequencing, viral load measurements, viral neutralization assays, detection of 75 autoantibodies, HLA genotype data, and serum proteomics covering 1,463 targets – to derive the most comprehensive view to-date of the biological features of COVID-19 disease severity. Our findings show that myeloid-derived suppressor cells (MDSCs) act as a key immunologic pivot point in severe COVID-19. Myeloid dysfunction, which is marked by impaired antigen presentation, drives a non-productive adaptive immune response, as reflected by reduced expression of B and T cell gene programs involved in antigen recognition, immune synapse formation, and cytotoxicity. Severe disease is also linked to autoantibodies targeting type I interferons, influenced by specific HLA-DQB1 allelic variants, and strongly correlated with serum IL-6 levels. Tocilizumab treatment eliminates CLU -expressing MDSCs and ISG-positive myeloid subsets, restores antigen presentation, and reactivates productive adaptive immunity. These changes align with improved clinical outcomes and better clinical laboratory measures, including reduced CRP. While many immunologic abnormalities in acute severe COVID-19 resolve during convalescence 3-months post-infection, we observed persistently high ICOS expression in regulatory T cells, potentially linking acute infection to chronic post-COVID syndromes. Overall, we define distinct innate and adaptive host immune responses associated with acute, IL-6–responsive, and convalescent SARS-CoV-2 infection. Our multimodal and high-dimensional dataset with curated clinical metadata provides a foundational and clinically relevant resource for modeling host immune response biology in health and disease.
Open AccessA multimodal atlas of COVID-19 severity identifies hallmarks of dysregulated immunity
The alpha-variant wave of the COVID-19 pandemic provided a unique opportunity to study, at single-cell resolution, how near-universal exposure to the same pathogen can lead to either effective or dysfunctional immune responses in humans. Although single-cell RNA-sequencing studies have characterized immune cellular features of COVID-19, they have not shown how tocilizumab treatment changes these features at single-cell resolution, or which features might persist into convalescence. In this study, we analyzed 2.5 million circulating immune cells from 428 patients across time points (840 PBMC samples), encompassing three contemporaneous SARS-CoV-2 cohorts: acutely infected patients across five WHO disease severity levels and three time points, patients from the first randomized control trial to study the efficacy of tocilizumab in the management of COVID-19, and convalescent patients three months after infection. We used linear modeling to integrate multiple data types – including single-cell RNA-seq, CITE-seq, TCR and BCR sequencing, viral load measurements, viral neutralization assays, detection of 75 autoantibodies, HLA genotype data, and serum proteomics covering 1,463 targets – to derive the most comprehensive view to-date of the biological features of COVID-19 disease severity. Our findings show that myeloid-derived suppressor cells (MDSCs) act as a key immunologic pivot point in severe COVID-19. Myeloid dysfunction, which is marked by impaired antigen presentation, drives a non-productive adaptive immune response, as reflected by reduced expression of B and T cell gene programs involved in antigen recognition, immune synapse formation, and cytotoxicity. Severe disease is also linked to autoantibodies targeting type I interferons, influenced by specific HLA-DQB1 allelic variants, and strongly correlated with serum IL-6 levels. Tocilizumab treatment eliminates CLU -expressing MDSCs and ISG-positive myeloid subsets, restores antigen presentation, and reactivates productive adaptive immunity. These changes align with improved clinical outcomes and better clinical laboratory measures, including reduced CRP. While many immunologic abnormalities in acute severe COVID-19 resolve during convalescence 3-months post-infection, we observed persistently high ICOS expression in regulatory T cells, potentially linking acute infection to chronic post-COVID syndromes. Overall, we define distinct innate and adaptive host immune responses associated with acute, IL-6–responsive, and convalescent SARS-CoV-2 infection. Our multimodal and high-dimensional dataset with curated clinical metadata provides a foundational and clinically relevant resource for modeling host immune response biology in health and disease.
- Open Access
BADLOCK: A Rapid, Portable, Inexpensive Diagnostic for Bacterial Pathogen and Resistance Detection in Resource-Limited Settings
Antimicrobial resistance is a major global health threat, with disproportionate impact in regions with limited diagnostic infrastructure. To address this challenge, we developed BADLOCK (Bacterial and AMR Detection by SHERLOCK), a rapid, low-cost molecular diagnostic platform for direct detection of bacterial pathogens and resistance genes from clinical samples. BADLOCK operates as a one-pot CRISPR-Cas13a reaction capable of detecting nine bacterial species and four major resistance genes directly from positive blood culture. It requires only a heat block and supports both fluorescence and paper-based lateral flow readouts. We validated BADLOCK on a prospectively collected clinical cohort of 194 blood culture specimens, supplemented with 69 mock samples generated from banked isolates enriched for targeted resistance genes. Across all cohorts, we conducted 2,224 individual reactions, achieving 97.6% accuracy (2,171/2,224) at the reaction level. At the assay level, 89.5% (274/306) showed perfect or partial concordance with gold-standard species and resistance gene detection, including 255 assays with perfect concordance and 19 with partial concordance (correct detection of at least one pathogen). This included an evaluation of BADLOCK as a potential culture-free diagnostic for urinary tract infections (UTIs), achieving 98.0% reaction-level accuracy. At the assay level, 90.7% (41/43) were perfectly concordant with gold-standard detection of both species and resistance genes, with 2 additional assays showing partial concordance. To our knowledge, this represents the first demonstration of the CRISPR-Cas13a diagnostic platform on clinical bloodstream infections to date and supports BADLOCK’s potential as a practical and scalable solution for rapid pathogen and resistance gene detection in resource-constrained settings.
Open AccessBADLOCK: A Rapid, Portable, Inexpensive Diagnostic for Bacterial Pathogen and Resistance Detection in Resource-Limited Settings
Antimicrobial resistance is a major global health threat, with disproportionate impact in regions with limited diagnostic infrastructure. To address this challenge, we developed BADLOCK (Bacterial and AMR Detection by SHERLOCK), a rapid, low-cost molecular diagnostic platform for direct detection of bacterial pathogens and resistance genes from clinical samples. BADLOCK operates as a one-pot CRISPR-Cas13a reaction capable of detecting nine bacterial species and four major resistance genes directly from positive blood culture. It requires only a heat block and supports both fluorescence and paper-based lateral flow readouts. We validated BADLOCK on a prospectively collected clinical cohort of 194 blood culture specimens, supplemented with 69 mock samples generated from banked isolates enriched for targeted resistance genes. Across all cohorts, we conducted 2,224 individual reactions, achieving 97.6% accuracy (2,171/2,224) at the reaction level. At the assay level, 89.5% (274/306) showed perfect or partial concordance with gold-standard species and resistance gene detection, including 255 assays with perfect concordance and 19 with partial concordance (correct detection of at least one pathogen). This included an evaluation of BADLOCK as a potential culture-free diagnostic for urinary tract infections (UTIs), achieving 98.0% reaction-level accuracy. At the assay level, 90.7% (41/43) were perfectly concordant with gold-standard detection of both species and resistance genes, with 2 additional assays showing partial concordance. To our knowledge, this represents the first demonstration of the CRISPR-Cas13a diagnostic platform on clinical bloodstream infections to date and supports BADLOCK’s potential as a practical and scalable solution for rapid pathogen and resistance gene detection in resource-constrained settings.
- Open Access
Longitudinal Immune Profiling in Sepsis Reveals Transient Expansion of a CD14 + Monocyte State and Persistent T Cell Suppression
Sepsis is a dynamic syndrome of immune dysregulation and a leading cause of global mortality. Although immune suppression is recognized as a hallmark of sepsis, the temporal dynamics and mechanistic drivers of immune dysfunction remain incompletely understood. Here, we performed longitudinal single-cell transcriptomic and proteomic profiling of peripheral blood from 98 adults with sepsis or sterile inflammation, alongside 12 healthy controls, capturing immune trajectories from initial clinical presentation through recovery. Integration of RNA and surface protein data revealed an early expansion of a transcriptionally reprogrammed CD14 + monocyte population (MS1) exhibiting features of monocytic myeloid-derived suppressor cells (M-MDSCs), including downregulation of HLA-DR and upregulation of alarmins ( S100A8 , S100A9 ), resistin, and clusterin. M-MDSCs arise from emergency myelopoiesis and contribute to adaptive immune suppression through impaired antigen presentation and T cell inhibition. MS1 abundance peaked at initial presentation and declined progressively during the first week of clinical management in most patients. In contrast, CD8 + naive and CD4 + memory T cells exhibited sustained depletion, with recovery occurring at convalescence in only a subset of patients. Plasma proteomic profiling identified cytokines and growth factors, including IL-6 and resistin, that may contribute to MS1 induction and suppressive activity. IL-6 exhibited a kinetic trajectory that closely paralleled MS1 abundance, peaking early and declining during recovery. Resistin levels were positively correlated with MS1 abundance across all timepoints from acute sepsis through convalescence. These dynamics suggest temporally distinct cytokine roles in initiating and sustaining immunosuppressive myeloid responses in sepsis. Together, these findings define a high-resolution, time-resolved immune atlas of human sepsis, linking emergency myelopoiesis to downstream adaptive immune suppression. Our results suggest that coordinated dynamics between myeloid and lymphoid compartments shape early immune trajectories in sepsis and highlight MDSC-targeting pathways as potential therapeutic avenues.
Open AccessLongitudinal Immune Profiling in Sepsis Reveals Transient Expansion of a CD14 + Monocyte State and Persistent T Cell Suppression
Sepsis is a dynamic syndrome of immune dysregulation and a leading cause of global mortality. Although immune suppression is recognized as a hallmark of sepsis, the temporal dynamics and mechanistic drivers of immune dysfunction remain incompletely understood. Here, we performed longitudinal single-cell transcriptomic and proteomic profiling of peripheral blood from 98 adults with sepsis or sterile inflammation, alongside 12 healthy controls, capturing immune trajectories from initial clinical presentation through recovery. Integration of RNA and surface protein data revealed an early expansion of a transcriptionally reprogrammed CD14 + monocyte population (MS1) exhibiting features of monocytic myeloid-derived suppressor cells (M-MDSCs), including downregulation of HLA-DR and upregulation of alarmins ( S100A8 , S100A9 ), resistin, and clusterin. M-MDSCs arise from emergency myelopoiesis and contribute to adaptive immune suppression through impaired antigen presentation and T cell inhibition. MS1 abundance peaked at initial presentation and declined progressively during the first week of clinical management in most patients. In contrast, CD8 + naive and CD4 + memory T cells exhibited sustained depletion, with recovery occurring at convalescence in only a subset of patients. Plasma proteomic profiling identified cytokines and growth factors, including IL-6 and resistin, that may contribute to MS1 induction and suppressive activity. IL-6 exhibited a kinetic trajectory that closely paralleled MS1 abundance, peaking early and declining during recovery. Resistin levels were positively correlated with MS1 abundance across all timepoints from acute sepsis through convalescence. These dynamics suggest temporally distinct cytokine roles in initiating and sustaining immunosuppressive myeloid responses in sepsis. Together, these findings define a high-resolution, time-resolved immune atlas of human sepsis, linking emergency myelopoiesis to downstream adaptive immune suppression. Our results suggest that coordinated dynamics between myeloid and lymphoid compartments shape early immune trajectories in sepsis and highlight MDSC-targeting pathways as potential therapeutic avenues.
- 28 March 2025
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 25  (1) , 1-69
Emerging role and clinical applications of circular RNAs in human diseases
Circular RNAs (circRNAs) are a large family of non-coding RNAs characterized by a single-stranded, covalently closed structure, predominantly synthesized through a back-splicing mechanism. While thousands of circRNAs have been identified, only a few have been functionally characterized. Although circRNAs are less abundant than other RNA types, they exhibit exceptional stability due to their covalently closed structure and demonstrate high cell and tissue specificity. CircRNAs play a critical role in maintaining cellular homeostasis by influencing gene transcription, translation, and post-translation processes, modulating the immune system, and interacting with mRNA, miRNA, and proteins. Abnormal circRNA expression has been associated with a wide range of human diseases and various infections. Due to their remarkable stability in body fluids and tissues, emerging research suggests that circRNAs could serve as diagnostic and therapeutic biomarkers for these diseases. This review focuses on the emerging role of circRNAs in various human diseases, exploring their biogenesis, molecular functions, and potential clinical applications as diagnostic and therapeutic biomarkers with current evidence, challenges, and future perspectives. The key theme highlights the significance of circRNAs in regulating gene expression, their involvement in diseases like cancer, neurodegenerative disorders, cardiovascular diseases, and diabetes, and their potential use in translational medicine for developing novel therapeutic strategies. We also discuss recent clinical trials involving circRNAs. Thus, this review is important for both basic researchers and clinical scientists, as it provides updated insights into the role of circRNAs in human diseases, aiding further exploration and advancements in the field.
- 28 March 2025
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 25  (1) , 1-69
Emerging role and clinical applications of circular RNAs in human diseases
Circular RNAs (circRNAs) are a large family of non-coding RNAs characterized by a single-stranded, covalently closed structure, predominantly synthesized through a back-splicing mechanism. While thousands of circRNAs have been identified, only a few have been functionally characterized. Although circRNAs are less abundant than other RNA types, they exhibit exceptional stability due to their covalently closed structure and demonstrate high cell and tissue specificity. CircRNAs play a critical role in maintaining cellular homeostasis by influencing gene transcription, translation, and post-translation processes, modulating the immune system, and interacting with mRNA, miRNA, and proteins. Abnormal circRNA expression has been associated with a wide range of human diseases and various infections. Due to their remarkable stability in body fluids and tissues, emerging research suggests that circRNAs could serve as diagnostic and therapeutic biomarkers for these diseases. This review focuses on the emerging role of circRNAs in various human diseases, exploring their biogenesis, molecular functions, and potential clinical applications as diagnostic and therapeutic biomarkers with current evidence, challenges, and future perspectives. The key theme highlights the significance of circRNAs in regulating gene expression, their involvement in diseases like cancer, neurodegenerative disorders, cardiovascular diseases, and diabetes, and their potential use in translational medicine for developing novel therapeutic strategies. We also discuss recent clinical trials involving circRNAs. Thus, this review is important for both basic researchers and clinical scientists, as it provides updated insights into the role of circRNAs in human diseases, aiding further exploration and advancements in the field.